Peter Lawrence, Cardurion CEO; Adam Koppel, Bain Capital Life Sciences managing director
A quiet cardio upstart makes some noise, getting $300M from Bain and diving deep into the clinic — with some real money for pipeline deals
The small executive team at Cardurion has been sticking carefully to its goals, in-licensing a lead cardio drug from Astellas in 2018 and making a careful trek into human studies as they advanced a follow-up program and gradually built out another preclinical prospect.
Involved in one of the most grindingly tough fields in drug R&D, they never thought much of touting their work. They did deals with Takeda and Pfizer without making much of a show of it. Even established a small operating unit in Japan. Polaris invested, but no one ever said how much — or much about why.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters